Benefit of pancreatic cancer screening
Full article:

Among people with an inherited mutation in a BRCA1 or BRCA2 gene, screening for pancreatic cancer found most cancers at an earlier stage when they could be treated by surgery. Posted 1/17/24)

Questions To Ask Your Health Care Provider

Open Clinical Trials

National Comprehensive Cancer Network (NCCN) Guidelines

The NCCN recommends the following screening for people at increased risk for pancreatic cancer: 

The NCCN recommends that people with inherited mutations in the following genes (with or without a family history of cancer) "consider pancreatic cancer screening" with MRCP or EUS:

NCCN guidelines recommend that people with an inherited mutation in one of the following genes and a family history of cancer "consider pancreatic cancer screening" with MRCP or EUS, beginning at age 50 or 10 years earlier than the earliest pancreatic cancer diagnosis in the family: ATMBRCA1BRCA2MLH1MSH2MSH6EPCAMPALB2TP53

The NCCN does not currently recommend pancreatic cancer screening for people with the above mutations who do not have a family history of cancer. 

American Society for Gastrointestinal Endoscopy (ASGE) Guidelines

In February 2022, the ASGE released updated guidelines on pancreatic cancer screening for people with a BRCA1 or BRCA2 mutation. These guidelines recommended:

The following studies are looking at risk management for pancreatic cancer:

A number of other clinical trials for pancreatic cancer screening and prevention may be found here.

The organization, Collaborative Group of the Americas- Inherited Gastrointestinal Cancer (CGA-IGC) curates an updated list of hospitals and programs with expertise in pancreatic cancer screening for high-risk people. 

Register for the FORCE Message Boards to get referrals from other members. Once you register, you can post on the Find a Specialist board to connect with other people who share your situation. 


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.